TY - JOUR

T1 - Effect of Empagliflozin on Multiple Biomarkers in Heart Failure

T2 - Insights From the Empire Heart Failure Trial

AU - Jensen, Jesper

AU - Omar, Massar

AU - Kistorp, Caroline

AU - Tuxen, Christian

AU - Poulsen, Mikael Kjær

AU - Faber, Jens

AU - Køber, Lars

AU - Gustafsson, Finn

AU - Møller, Jacob Eifer

AU - Schou, Morten

N1 - Funding Information: The Empire HF (Heart Failure) trial was supported by the Danish Heart Foundation, Copenhagen, Denmark (grants 17-R116-A7714-22076 and 18-R124-A8573-22107); the Research Council at Herlev and Gentofte University Hospital, Herlev, Denmark (institutional research grant); the Research and Innovation Foundation of the Department of Cardiology (FUHAS, formerly FUKAP), Herlev and Gentofte University Hospital, Herlev, Denmark (institutional research grant); the A.P. Møller Foundation for the Advancement of Medical Science, Copenhagen, Denmark (grant 17-L-0002); Steno Diabetes Center Odense, Odense, Denmark (institutional research grant); and the Capital Region of Denmark, Copenhagen, Denmark (grant A6058). Thermo Fischer Scientific (Hennigsdorf, Germany) funded the endothelin-1 kits. The manufacturer of empagliflozin had no role in any aspect of the study. Funding Information: Dr Jensen reports grants from the Research Council at Herlev and Gentofte University Hospital, Herlev, Denmark, grants from the Research and Innovation Foundation of the Department of Cardiology (FUHAS, formerly FUKAP), Herlev and Gentofte University Hospital, Herlev, Denmark, and grants from the A.P. Møller Foundation for the Advancement of Medical Science, Copenhagen, Denmark, during the conduct of the study; and grants from the Danish Heart Foundation and personal fees from scientific advisory board from AstraZeneca and Boehringer Ingelheim, outside the submitted work. Dr Omar reports grants from the Steno Diabetes Center Odense, Odense, Denmark, during the conduct of the study. Dr Kistorp reports personal fees from scientific advisory panel and speaker fees from Boehringer Ingelheim, Merck, Sharp & Dohme, AstraZeneca, Amgen, Novartis, Novo Nordisk, and Shire, outside the submitted work. Dr Tuxen reports personal fees from scientific advisory board and speaker fees from Bayer and Orion Pharma outside the submitted work. Dr Køber reports and personal fees from speaker honorarium from Novartis, AstraZeneca, Novo Nordisk, and Boehringer Ingelheim, outside the submitted work. Dr Gustafsson reports personal fees from scientific advisory panel and speaker fees from AstraZeneca, Boehringer Ingelheim, Abbott, Orion Pharma, Pfizer, and Novartis, and acting as an unpaid advisor for Corvia, outside the submitted work. Dr Møller reports grants from Abiomed Inc, and personal fees from speaker honorarium from Novartis and Orion Pharma, outside the submitted work. Dr Schou reports grants from the Danish Heart Foundation, Copenhagen, Denmark, and from the Capital Region of Denmark, Copenhagen, Denmark, during the conduct of the study; personal fees from speaker honorarium and nonfinancial support (as the national lead investigator of the DAPA-HF trial [Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure]) from AstraZeneca, and personal fees from speaker honorarium from Novo Nordisk and Boehringer Ingelheim, outside the submitted work. The other authors report no conflicts.

PY - 2022

Y1 - 2022

KW - biomarkers

KW - clinical trial

KW - heart failure

KW - sodium-glucose transporter 2 inhibitors

KW - therapeutics

U2 - 10.1161/CIRCHEARTFAILURE.121.009333

DO - 10.1161/CIRCHEARTFAILURE.121.009333

M3 - Letter

C2 - 35973031

AN - SCOPUS:85136020997

VL - 15

SP - 799

EP - 801

JO - Circulation: Heart Failure

JF - Circulation: Heart Failure

SN - 1941-3289

IS - 8

ER -